Real-world evidence on the risk of cancer with anti-IL-5 and anti-IL-4Ra biologicals

Allergy. 2023 May;78(5):1375-1377. doi: 10.1111/all.15628. Epub 2023 Jan 11.

Authors

Diogo Mota¹, Tiago Azenha Rama^{1

2

3

4}, André Moreira^{1

2

3

4}

Affiliations

¹ Serviço de Imunoalergologia, Centro Hospitalar Universitário São João, Porto, Portugal.
² Serviço de Imunologia Básica e Clínica, Departamento de Patologia, Faculdade de Medicina, Universidade do Porto, Porto, Portugal.
³ EPIUnit - Institute of Public Health, University of Porto, Porto, Portugal.
⁴ Laboratory for Integrative and Translational Research in Population Health (ITR), Porto, Portugal.

PMID: 36572508
DOI: 10.1111/all.15628

No abstract available

Publication types

Letter

MeSH terms

Biological Products* / adverse effects
Humans
Interleukin-5 / metabolism
Neoplasms* / epidemiology
Neoplasms* / etiology
Receptors, Interleukin-4 / immunology

Substances

Biological Products
Interleukin-5
Receptors, Interleukin-4